The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Efalizumab for Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial
Abstract
CONTEXT: Because T-cell interactions are involved in the pathophysiology of psoriasis, therapy with a T-cell modulator may have beneficial effects on psoriasis severity and health-related quality of life (HRQL). OBJECTIVE: To assess the efficacy and safety of efalizumab, a T-cell modulator, in patients with plaque psoriasis. DESIGN, SETTING, AND PATIENTS: Phase 3 randomized, double-blind, parallel-group, placebo-controlled trial involving 556 adult patients with stable, moderate to severe plaque psoriasis and conducted at 30 study centers in the United States and Canada between January and July 2002. INTERVENTIONS: Patients were randomly assigned in a 2:1 ratio to receive 12 weekly doses of subcutaneous efalizumab, 1 mg/kg (n = 369), or placebo equivalent (n = 187). MAIN OUTCOME MEASURES: At least 75% improvement on the Psoriasis Area and Severity Index (PASI-75); improvement on the overall Dermatology Life Quality Index (DLQI), Itching Visual Analog Scale (VAS), and Psoriasis Symptom Assessment (PSA) at week 12 vs baseline. RESULTS: Efalizumab-treated patients experienced significantly greater improvement on all end points than placebo-treated patients. Twenty-seven percent of efalizumab-treated patients achieved PASI-75 vs 4% of the placebo group ( P<.001). Efalizumab-treated patients exhibited significantly greater mean percentage improvement than placebo-treated patients on the overall DLQI (47% vs 14%; P<.001), Itching VAS (38% vs -0.2%; P<.001), and PSA frequency and severity subscales (48% vs 18% and 47% vs 17%, respectively; P<.001 for both) at the first assessment point. Efalizumab was safe and well tolerated, with primarily mild to moderate adverse events. CONCLUSION: In this 12-week study, efalizumab resulted in significant improvements in clinical end points, including physician-assessed and dermatology-specific patient-reported HRQL measures, in patients with moderate to severe plaque psoriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Psoriasis causes as much disability as other major medical diseases
Rapp, S. R., Feldman, S. R., Exum, M. L., Fleischer, A. B., & Reboussin, D. M. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70112-x · Cited by 1,491
Springer, T. (1987) · Annual Review of Immunology · doi:10.1146/annurev.immunol.5.1.223 · Cited by 1,110
Dustin, M. L., & Springer, T. A. (1988) · The Journal of cell biology · doi:10.1083/jcb.107.1.321 · Cited by 985
Psoriasis − epidemiology and clinical spectrum
Christophers, E. (2001) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2001.00832.x · Cited by 972
Krueger, G. G., Koo, J. Y. M., Lebwohl, M., Menter, A., Stern, R. S., & Rolstad, T. (2001) · PubMed · Cited by 969
Self-citationGupta, & Gupta (1998) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1998.02511.x · Cited by 864
Chren, M.-M., Lasek, R. J., Quinn, L. M., Mostow, E. N., & Zyzanski, S. J. (1996) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12365600 · Cited by 699
Gottlieb, S. L., Gilleaudeau, P., Johnson, R., Estes, L., Woodworth, T. G., Gottlieb, A. B., & Krueger, J. G. (1995) · Nature Medicine · doi:10.1038/nm0595-442 · Cited by 606
The immunologic basis for the treatment of psoriasis with new biologic agents
Krueger, J. G. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120568 · Cited by 600
A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis
Lebwohl, M., Tyring, S. K., Hamilton, T. K., Toth, D., Glazer, S., Tawfik, N. H., Walicke, P., Dummer, W., Wang, X., Garovoy, M. R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030002 · Cited by 570
Self-citationThe effect of severe psoriasis on the quality of life of 369 patients
Finlay, A. Y., & Coles, E. C. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1995.tb05019.x · Cited by 550
Role of Lymphocyte Adhesion Receptors in Transient Interactions and Cell Locomotion
Dustin, M. L., & Springer, T. A. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.000331 · Cited by 529
Greaves, M. W., & Weinstein, G. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503023320907 · Cited by 512
The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis
Yosipovitch, G., Goon, A., Wee, J., Chan, Y. H., & Goh, C. L. (2000) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2000.03829.x · Cited by 446
Chren, M. (1997) · Archives of Dermatology · doi:10.1001/archderm.133.11.1433 · Cited by 446
Ashcroft, Po, L. W., Williams, & Griffiths (1999) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1999.02963.x · Cited by 287
The pathogenesis of psoriasis: immunological facts and speculations
Bos, J. D., & De Rie, M. A. (1999) · Immunology Today · doi:10.1016/s0167-5699(98)01381-4 · Cited by 284
Quantifying the harmful effect of psoriasis on health-related quality of life
Weiss, S. C., Kimball, A. B., Liewehr, D. J., Blauvelt, A., Turner, M. L., & Emanuel, E. J. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.122755 · Cited by 265
Gottlieb, A. B., Krueger, J. G., Wittkowski, K., Dedrick, R., Walicke, P. A., & Garovoy, M. (2002) · Archives of Dermatology · doi:10.1001/archderm.138.5.591 · Cited by 230
Self-citationNickoloff, B. J., Griffiths, C. E. M., & Barker, J. N. W. N. (1990) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12876134 · Cited by 209
Gottlieb, A., Krueger, J. G., Bright, R., Ling, M., Lebwohl, M., Kang, S., Feldman, S., Spellman, M., Wittkowski, K., Ochs, H. D., et al. (2000) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(00)90214-7 · Cited by 201
The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress.
Gupta, M. A., & Gupta, A. K. (1995) · Acta Dermato-Venereologica · doi:10.2340/0001555575240243 · Cited by 196
Gupta, M. A. (1988) · Archives of Dermatology · doi:10.1001/archderm.1988.01670070040016 · Cited by 154
Werther, W., González, T., O'Connor, S. L., McCabe, S., Chan, B., Hotaling, T. E., Champe, M., Fox, J. A., Jardieu, P. M., Berman, P. W., et al. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4986 · Cited by 148
T-Lymphocyte Dependence of Psoriatic Pathology in Human Psoriatic Skin Grafted to SCID Mice
Gilhar, A., David, M., Ullmann, Y., Berkutski, T., & Kalish, R. S. (1997) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12335758 · Cited by 126
The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort
McKenna, K. E., & Stern, R. S. (1997) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(97)80214-9 · Cited by 119
Wahl, A. K., Loge, J. H., Wiklund, I. E., & Hanestad, B. R. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.107501 · Cited by 114
Leary, M. R., Rapp, S. R., Herbst, K. C., Exum, M. L., & Feldman, S. R. (1998) · Health Psychology · doi:10.1037//0278-6133.17.6.530 · Cited by 104
Kuypers, T. W., & Ross, D. (1989) · Research in Immunology · doi:10.1016/0923-2494(89)90114-4 · Cited by 45
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Gottlieb, A., Feldman, S. R., Van Voorhees, A. S., Leonardi, C. L., Gordon, K. B., Lebwohl, M., Koo, J. Y. M., Elmets, C. A., Korman, N. J., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.039 · Cited by 1,222
Self-citationReich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Self-citationBasra, M. K. A., Fenech, R., Gatt, R. M., Salek, M. S., & Finlay, A. Y. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08832.x · Cited by 789
Metadata
- Authors
- Gordon, K. B., Papp, K. A., Hamilton, T. K., Walicke, P. A., Dummer, W., Li, N., Bresnahan, B. W., Menter, A., & for the Efalizumab Study Group
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2003-12-17
- Volume
- 290
- Issue
- 23
- Pages
- 3073
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2034585843
- Cited by
- 391
- References
- 31
- FWCI
- 14.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.